Leader
|
|
|
00000nz a2200037n 45 0 |
001
|
|
|
WKP|Q45293273
(VIAF cluster)
(Authority/Source Record)
|
003
|
|
|
WKP |
005
|
|
|
20241121000107.0 |
008
|
|
|
241121nneanz||abbn n and d |
035
|
|
|
‡a
(WKP)Q45293273
|
024
|
|
|
‡a
0000-0002-8357-2658
‡2
orcid
|
024
|
|
|
‡a
6603693525
‡2
scopus
|
035
|
|
|
‡a
(OCoLC)Q45293273
|
100
|
0 |
|
‡a
Emilio Di Maria
‡c
researcher
‡9
en
|
375
|
|
|
‡a
1
‡2
iso5218
|
400
|
0 |
|
‡a
Emilio Di Maria
‡c
wetenschapper
‡9
nl
|
670
|
|
|
‡a
Author's 19q13 microdeletion syndrome: Further refining the critical region.
|
670
|
|
|
‡a
Author's 3q26.33-3q27.2 microdeletion: a new microdeletion syndrome?
|
670
|
|
|
‡a
Author's A family with autosomal dominant mutilating neuropathy not linked to either Charcot-Marie-Tooth disease type 2B
|
670
|
|
|
‡a
Author's A family with autosomal dominant mutilating neuropathy not linked to either Charcot-Marie-Tooth disease type 2B (CMT2B) or hereditary sensory neuropathy type I (HSN I) loci
|
670
|
|
|
‡a
Author's A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference.
|
670
|
|
|
‡a
Author's A patient with a skull defect, dysmorphic features, hypopituitarism, and abnormal cortical development
|
670
|
|
|
‡a
Author's A putative regulatory subunit
|
670
|
|
|
‡a
Author's A putative regulatory subunit (NR3A) of the NMDA receptor complex as candidate gene for susceptibility to schizophrenia: a case-control study
|
670
|
|
|
‡a
Author's A single nucleotide variant in the FMR1 CGG repeat results in a "Pseudodeletion" and is not associated with the fragile X syndrome phenotype.
|
670
|
|
|
‡a
Author's Arthropathy, osteolysis, keloids, relapsing conjunctival pannus and gingival overgrowth: A variant of polyfibromatosis?
|
670
|
|
|
‡a
Author's Clinical and genetic characteristics of late-onset Huntington's disease
|
670
|
|
|
‡a
Author's Clinical and genetic study of essential tremor in the Italian population
|
670
|
|
|
‡a
Author's Congenital hypomyelination due to myelin protein zero Q215X mutation
|
670
|
|
|
‡a
Author's Does parkin play a role in the peripheral nervous system? A family report
|
670
|
|
|
‡a
Author's Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriers
|
670
|
|
|
‡a
Author's Essential tremor is not associated with alpha-synuclein gene haplotypes
|
670
|
|
|
‡a
Author's Exclusion of the ninjurin gene as a candidate for hereditary sensory neuropathies type I and type II
|
670
|
|
|
‡a
Author's Family and molecular data for a fine analysis of age at onset in Huntington disease.
|
670
|
|
|
‡a
Author's Friedreich's ataxia: a new mutation in two compound heterozygous siblings with unusual clinical onset
|
670
|
|
|
‡a
Author's Genetic Counseling and Testing for Alzheimer's Disease and Frontotemporal Lobar Degeneration: An Italian Consensus Protocol.
|
670
|
|
|
‡a
Author's Genetic counselling and testing for inherited dementia: single-centre evaluation of the consensus Italian DIAfN protocol
|
670
|
|
|
‡a
Author's Genetic variants of the human host influencing the coronavirus-associated phenotypes (SARS, MERS and COVID-19): rapid systematic review and field synopsis
|
670
|
|
|
‡a
Author's Genetic variation in the G720/G30 gene locus
|
670
|
|
|
‡a
Author's Genetic variation in the G720/G30 gene locus (DAOA) influences the occurrence of psychotic symptoms in patients with Alzheimer's disease
|
670
|
|
|
‡a
Author's Hereditary sensory neuropathy is caused by a mutation in the delta subunit of the cytosolic chaperonin-containing t-complex peptide-1 (Cct4 ) gene
|
670
|
|
|
‡a
Author's How is genetic testing evaluated? A systematic review of the literature.
|
670
|
|
|
‡a
Author's Inclusion body myopathy, Paget's disease of the bone and frontotemporal dementia: recurrence of the VCP R155H mutation in an Italian family and implications for genetic counselling.
|
670
|
|
|
‡a
Author's Is a proper name the proper name? A survey on attitude of clinical geneticists towards eponyms in Italy
|
670
|
|
|
‡a
Author's Is Hardikar syndrome distinct from Kabuki (Niikawa-Kuroki) syndrome?
|
670
|
|
|
‡a
Author's Mental function in males and females.
|
670
|
|
|
‡a
Author's Mutational analysis of parkin gene by denaturing high-performance liquid chromatography
|
670
|
|
|
‡a
Author's Mutational analysis of parkin gene by denaturing high-performance liquid chromatography (DHPLC) in essential tremor.
|
670
|
|
|
‡a
Author's No evidence of association between BDNF gene variants and age-at-onset of Huntington's disease
|
670
|
|
|
‡a
Author's No evidence of association between CAG expansions and essential tremor in a large cohort of Italian patients
|
670
|
|
|
‡a
Author's Possible influence of a non-synonymous polymorphism located in the NGF precursor on susceptibility to late-onset Alzheimer's disease and mild cognitive impairment
|
670
|
|
|
‡a
Author's Predicting Response to Neoadjuvant Therapy in Colorectal Cancer Patients the Role of Messenger-and Micro-RNA Profiling
|
670
|
|
|
‡a
Author's Recurrence of Mowat-Wilson syndrome in siblings with a novel mutation in the ZEB2 gene
|
670
|
|
|
‡a
Author's Recurrent, Activating Variants in the Receptor Tyrosine Kinase DDR2 Cause Warburg-Cinotti Syndrome.
|
670
|
|
|
‡a
Author's Search for mutations in the EGR2 corepressor proteins, NAB1 and NAB2, in human peripheral neuropathies
|
670
|
|
|
‡a
Author's Severe fluoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2/U ratio evaluation
|
670
|
|
|
‡a
Author's The -413C > G substitution in the promoter of the FMR1 gene is not associated with the fragile X syndrome phenotype.
|
670
|
|
|
‡a
Author's The D355V mutation decreases EGR2 binding to an element within the Cx32 promoter
|
670
|
|
|
‡a
Author's The H1 haplotype of the tau gene
|
670
|
|
|
‡a
Author's The H1 haplotype of the tau gene (MAPT) is associated with mild cognitive impairment.
|
670
|
|
|
‡a
Author's The policy of public health genomics in Italy
|
670
|
|
|
‡a
Author's The refinement of the critical region for the 2q31.2q32.3 deletion syndrome indicates candidate genes for mental retardation and speech impairment.
|
909
|
|
|
‡a
(orcid) 0000000283572658
‡9
1
|
909
|
|
|
‡a
(scopus) 6603693525
‡9
1
|
912
|
|
|
‡a
clinicalandgeneticcharacteristicsoflateonsethuntingtonsdisease
‡A
Clinical and genetic characteristics of late-onset Huntington's disease
‡9
1
|
919
|
|
|
‡a
19q13microdeletionsyndromefurtherrefiningthecriticalregion
‡A
19q13 microdeletion syndrome: Further refining the critical region.
‡9
1
|
919
|
|
|
‡a
3q26333q272microdeletionanewmicrodeletionsyndrome
‡A
3q26.33-3q27.2 microdeletion: a new microdeletion syndrome?
‡9
1
|
919
|
|
|
‡a
familywithautosomaldominantmutilatingneuropathynotlinkedtoeithercharcotmarietoothdiseasetype2b
‡A
A family with autosomal dominant mutilating neuropathy not linked to either Charcot-Marie-Tooth disease type 2B
‡9
1
|
919
|
|
|
‡a
familywithautosomaldominantmutilatingneuropathynotlinkedtoeithercharcotmarietoothdiseasetype2bcmt2borhereditarysensoryneuropathytype1hsn1loci
‡A
A family with autosomal dominant mutilating neuropathy not linked to either Charcot-Marie-Tooth disease type 2B (CMT2B) or hereditary sensory neuropathy type I (HSN I) loci
‡9
1
|
919
|
|
|
‡a
majorityofhuntingtonsdiseasepatientsmaybetreatablebyindividualizedallelespecificrnainterference
‡A
A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference.
‡9
1
|
919
|
|
|
‡a
patientwithaskulldefectdysmorphicfeatureshypopituitarismandabnormalcorticaldevelopment
‡A
A patient with a skull defect, dysmorphic features, hypopituitarism, and abnormal cortical development
‡9
1
|
919
|
|
|
‡a
putativeregulatorysubunit
‡A
A putative regulatory subunit
‡9
1
|
919
|
|
|
‡a
putativeregulatorysubunitnr3aofthenmdareceptorcomplexascandidategeneforsusceptibilitytoschizophreniaacasecontrolstudy
‡A
A putative regulatory subunit (NR3A) of the NMDA receptor complex as candidate gene for susceptibility to schizophrenia: a case-control study
‡9
1
|
919
|
|
|
‡a
singlenucleotidevariantinthefmr1cggrepeatresultsinapseudodeletionandisnotassociatedwiththefragile10syndromephenotype
‡A
A single nucleotide variant in the FMR1 CGG repeat results in a "Pseudodeletion" and is not associated with the fragile X syndrome phenotype.
‡9
1
|
919
|
|
|
‡a
arthropathyosteolysiskeloidsrelapsingconjunctivalpannusandgingivalovergrowthavariantofpolyfibromatosis
‡A
Arthropathy, osteolysis, keloids, relapsing conjunctival pannus and gingival overgrowth: A variant of polyfibromatosis?
‡9
1
|
919
|
|
|
‡a
clinicalandgeneticstudyofessentialtremorintheitalianpopulation
‡A
Clinical and genetic study of essential tremor in the Italian population
‡9
1
|
919
|
|
|
‡a
congenitalhypomyelinationduetomyelinprotein0q215xmutation
‡A
Congenital hypomyelination due to myelin protein zero Q215X mutation
‡9
1
|
919
|
|
|
‡a
doesparkinplayaroleintheperipheralnervoussystemafamilyreport
‡A
Does parkin play a role in the peripheral nervous system? A family report
‡9
1
|
919
|
|
|
‡a
dopaminetransporterimagingstudyinparkinsonismoccurringinfragile10premutationcarriers
‡A
Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriers
‡9
1
|
919
|
|
|
‡a
essentialtremorisnotassociatedwithalphasynucleingenehaplotypes
‡A
Essential tremor is not associated with alpha-synuclein gene haplotypes
‡9
1
|
919
|
|
|
‡a
exclusionoftheninjuringeneasacandidateforhereditarysensoryneuropathiestype1andtype2
‡A
Exclusion of the ninjurin gene as a candidate for hereditary sensory neuropathies type I and type II
‡9
1
|
919
|
|
|
‡a
familyandmoleculardataforafineanalysisofageatonsetinhuntingtondisease
‡A
Family and molecular data for a fine analysis of age at onset in Huntington disease.
‡9
1
|
919
|
|
|
‡a
friedreichsataxiaanewmutationin2compoundheterozygoussiblingswithunusualclinicalonset
‡A
Friedreich's ataxia: a new mutation in two compound heterozygous siblings with unusual clinical onset
‡9
1
|
919
|
|
|
‡a
geneticcounselingandtestingforalzheimersdiseaseandfrontotemporallobardegenerationanitalianconsensusprotocol
‡A
Genetic Counseling and Testing for Alzheimer's Disease and Frontotemporal Lobar Degeneration: An Italian Consensus Protocol.
‡9
1
|
919
|
|
|
‡a
geneticcounsellingandtestingforinheriteddementiasinglecentreevaluationoftheconsensusitaliandiafnprotocol
‡A
Genetic counselling and testing for inherited dementia: single-centre evaluation of the consensus Italian DIAfN protocol
‡9
1
|
919
|
|
|
‡a
geneticvariantsofthehumanhostinfluencingthecoronavirusassociatedphenotypessarsmersandcovid19rapidsystematicreviewandfieldsynopsis
‡A
Genetic variants of the human host influencing the coronavirus-associated phenotypes (SARS, MERS and COVID-19): rapid systematic review and field synopsis
‡9
1
|
919
|
|
|
‡a
geneticvariationintheg720g30genelocus
‡A
Genetic variation in the G720/G30 gene locus
‡9
1
|
919
|
|
|
‡a
geneticvariationintheg720g30genelocusdaoainfluencestheoccurrenceofpsychoticsymptomsinpatientswithalzheimersdisease
‡A
Genetic variation in the G720/G30 gene locus (DAOA) influences the occurrence of psychotic symptoms in patients with Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
hereditarysensoryneuropathyiscausedbyamutationinthedeltasubunitofthecytosolicchaperonincontainingtcomplexpeptide1cct4gene
‡A
Hereditary sensory neuropathy is caused by a mutation in the delta subunit of the cytosolic chaperonin-containing t-complex peptide-1 (Cct4 ) gene
‡9
1
|
919
|
|
|
‡a
howisgenetictestingevaluatedasystematicreviewoftheliterature
‡A
How is genetic testing evaluated? A systematic review of the literature.
‡9
1
|
919
|
|
|
‡a
inclusionbodymyopathypagetsdiseaseoftheboneandfrontotemporaldementiarecurrenceofthevcpr155hmutationinanitalianfamilyandimplicationsforgeneticcounselling
‡A
Inclusion body myopathy, Paget's disease of the bone and frontotemporal dementia: recurrence of the VCP R155H mutation in an Italian family and implications for genetic counselling.
‡9
1
|
919
|
|
|
‡a
isapropernamethepropernameasurveyonattitudeofclinicalgeneticiststowardseponymsinitaly
‡A
Is a proper name the proper name? A survey on attitude of clinical geneticists towards eponyms in Italy
‡9
1
|
919
|
|
|
‡a
ishardikarsyndromedistinctfromkabukiniikawakurokisyndrome
‡A
Is Hardikar syndrome distinct from Kabuki (Niikawa-Kuroki) syndrome?
‡9
1
|
919
|
|
|
‡a
mentalfunctioninmalesandfemales
‡A
Mental function in males and females.
‡9
1
|
919
|
|
|
‡a
mutationalanalysisofparkingenebydenaturinghighperformanceliquidchromatography
‡A
Mutational analysis of parkin gene by denaturing high-performance liquid chromatography
‡9
1
|
919
|
|
|
‡a
mutationalanalysisofparkingenebydenaturinghighperformanceliquidchromatographydhplcinessentialtremor
‡A
Mutational analysis of parkin gene by denaturing high-performance liquid chromatography (DHPLC) in essential tremor.
‡9
1
|
919
|
|
|
‡a
noevidenceofassociationbetweenbdnfgenevariantsandageatonsetofhuntingtonsdisease
‡A
No evidence of association between BDNF gene variants and age-at-onset of Huntington's disease
‡9
1
|
919
|
|
|
‡a
noevidenceofassociationbetweencagexpansionsandessentialtremorinalargecohortofitalianpatients
‡A
No evidence of association between CAG expansions and essential tremor in a large cohort of Italian patients
‡9
1
|
919
|
|
|
‡a
possibleinfluenceofanonsynonymouspolymorphismlocatedinthengfprecursoronsusceptibilitytolateonsetalzheimersdiseaseandmildcognitiveimpairment
‡A
Possible influence of a non-synonymous polymorphism located in the NGF precursor on susceptibility to late-onset Alzheimer's disease and mild cognitive impairment
‡9
1
|
919
|
|
|
‡a
predictingresponsetoneoadjuvanttherapyincolorectalcancerpatientstheroleofmessengerandmicrornaprofiling
‡A
Predicting Response to Neoadjuvant Therapy in Colorectal Cancer Patients the Role of Messenger-and Micro-RNA Profiling
‡9
1
|
919
|
|
|
‡a
recurrenceofmowatwilsonsyndromeinsiblingswithanovelmutationinthezeb2gene
‡A
Recurrence of Mowat-Wilson syndrome in siblings with a novel mutation in the ZEB2 gene
‡9
1
|
919
|
|
|
‡a
recurrentactivatingvariantsinthereceptortyrosinekinaseddr2causewarburgcinottisyndrome
‡A
Recurrent, Activating Variants in the Receptor Tyrosine Kinase DDR2 Cause Warburg-Cinotti Syndrome.
‡9
1
|
919
|
|
|
‡a
searchformutationsintheegr2corepressorproteinsnab1andnab2inhumanperipheralneuropathies
‡A
Search for mutations in the EGR2 corepressor proteins, NAB1 and NAB2, in human peripheral neuropathies
‡9
1
|
919
|
|
|
‡a
severefluoropyrimidinerelatedtoxicityclinicalimplicationsofdpydanalysisanduh2uratioevaluation
‡A
Severe fluoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2/U ratio evaluation
‡9
1
|
919
|
|
|
‡a
413cgsubstitutioninthepromoterofthefmr1geneisnotassociatedwiththefragile10syndromephenotype
‡A
The -413C > G substitution in the promoter of the FMR1 gene is not associated with the fragile X syndrome phenotype.
‡9
1
|
919
|
|
|
‡a
d355vmutationdecreasesegr2bindingtoanelementwithinthecx32promoter
‡A
The D355V mutation decreases EGR2 binding to an element within the Cx32 promoter
‡9
1
|
919
|
|
|
‡a
h1haplotypeofthetaugene
‡A
The H1 haplotype of the tau gene
‡9
1
|
919
|
|
|
‡a
h1haplotypeofthetaugenemaptisassociatedwithmildcognitiveimpairment
‡A
The H1 haplotype of the tau gene (MAPT) is associated with mild cognitive impairment.
‡9
1
|
919
|
|
|
‡a
policyofpublichealthgenomicsinitaly
‡A
The policy of public health genomics in Italy
‡9
1
|
919
|
|
|
‡a
refinementofthecriticalregionforthe2q312q323deletionsyndromeindicatescandidategenesformentalretardationandspeechimpairment
‡A
The refinement of the critical region for the 2q31.2q32.3 deletion syndrome indicates candidate genes for mental retardation and speech impairment.
‡9
1
|
946
|
|
|
‡a
b
‡9
1
|
996
|
|
|
‡2
SUDOC|26926230X
|
996
|
|
|
‡2
RERO|A012061727
|
996
|
|
|
‡2
JPG|500110207
|
996
|
|
|
‡2
ISNI|0000000083174874
|
996
|
|
|
‡2
PTBNP|66446
|
996
|
|
|
‡2
ISNI|0000000066309693
|
996
|
|
|
‡2
LC|no2009004807
|
996
|
|
|
‡2
ISNI|0000000382040833
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
998
|
|
|
‡a
Di Maria, Emilio
‡2
DNB|1230452966
‡3
standard number
|